Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 263-272 , April 2008

99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor

  • Stephanie R. Lane

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • Department of Chemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Bhadrasetty Veerendra

      Affiliations

    • Department of Radiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • ,
  • Tammy L. Rold

      Affiliations

    • Department of Internal Medicine, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • ,
  • Gary L. Sieckman

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Timothy J. Hoffman

      Affiliations

    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • Department of Chemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Silvia S. Jurisson

      Affiliations

    • Department of Chemistry, University of Missouri-Columbia, Columbia, MO 65211, USA
    • ,
  • Charles J. Smith

      Affiliations

    • Department of Radiology, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • Research Division, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • University of Missouri Research Reactor Center, University of Missouri-Columbia, Columbia, MO 65211, USA
    • The Radiopharmaceutical Sciences Institute, University of Missouri-Columbia School of Medicine, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding author. Harry S. Truman Memorial VA Hospital, Columbia, MO 65201, USA. Tel.: +1 573 814 6000x3683; fax: +1 573 882 1663.

Received 2 October 2007 ,Revised 26 October 2007 ,Accepted 17 November 2007.

References 

  1. West SD, Mercer DW. Bombesin-induced gastroprotection. Ann Surg. 2005;241:227–231
  2. Fleischmann A, Läderach U, Friess H, Buechler MW, Reubi JC. Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest. 2000;80:1807–1817
  3. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] Conjugate: a novel targeting vector for positron emission tomographic imaging of gastrin releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A. 2007;104:12462–12467
  4. Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327–1337
  5. de Visser M, Bernard HF, Erion LJ, Schmidt MA, Srinivasan A, Waser B, et al. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumors. Eur J Nucl Med Mol Imaging. 2007;34:1228–1238
  6. Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, et al. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). Bioconjug Chem. 2007;18:724–730
  7. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175–183
  8. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng F, Chen J, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144–1152
  9. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492–501
  10. Montet X, Yuan H, Weissleder R, Josephson L. Enzyme-based visualization of receptor-ligand binding in tissues. Lab Invest. 2006;86:517–525
  11. Garcia-Garayoa E, Ruegg D, Blauenstein P, Zwimpfer M, Khan IU, Maes V, et al. Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol. 2007;34:17–28
  12. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110–1117
  13. Veerendra B, Sieckman GL, Hoffman TJ, Rold T, Retzloff L, McCrate J, et al. Synthesis, radiolabeling and in vitro GRP receptor targeting studies of 99mTc-Triaza-X-BBN[7-14]NH2 (X=serylserylserine, glycylglycylglycine, glycylserylglycine, or beta-alanine). Synth React Inorg Met-Org Nano-Met Chem. 2006;36:481–491
  14. Marti N, Spingler B, Schibli R. Comparative studies of substitution reactions of rhenium(I) dicarbonyl–nitrosyl and tricarbonyl complexes in aqueous media. Inorg Chem. 2005;44:6082–6091
  15. Méndez-Rojas MA, Kharisov BI, Tsivadze AY. Recent advances on technetium complexes: coordination chemistry and medical applications. J Coord Chem. 2006;59:1–63
  16. Banerjee SR, Babich JW, Zubieta J. A new bifunctional amino acid chelator targeting the glucose transporter. Inorganica Chim Acta. 2006;359:1603–1612
  17. Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med. 2002;29:1529–1542
  18. Abram U, Alberto R. Technetium and rhenium—coordination chemistry and nuclear medical applications. J Braz Chem Soc. 2006;17:1486–1500
  19. Maria L, Cunha S, Videira M, Gano L, Paulo A, Santos IC. Rhenium and technetium tricarbonyl complexes anchored by pyrazole-based tripods: novel lead structures for the design of myocardial imaging agents. Dalton Trans. 2007;28:3010–3019
  20. Banerjee SR, Babich JW, Zubieta J. Bifunctional chelates with aliphatic amine donors for labeling of biomolecules with the {Tc(CO)3}+ and {Re(CO)3}+ cores: the crystal and molecular structure of [Re(CO)3{(H2NCH2CH2)2N(CH2)4CO2Me}]Br. Inorg Chem Commun. 2004;7:481–484
  21. Wei L, Babich J, Zubieta J. Bifunctional chelates with mixed aromatic and aliphatic amine donors for labeling of biomolecules with the {Tc(CO)3}+ and {Re(CO)3}+ cores. Inorganica Chim Acta. 2005;358:3691–3700
  22. Pearson RG. Hard and soft acids and bases. J Am Chem Soc. 1963;85:3533–3539
  23. Pearson RG. Hard and soft acids and bases, part I, fundamental principles. J Chem Ed. 1968;45:581–587
  24. Pearson RG. Hard and soft acids and bases, part II, underlying theories. J Chem Ed. 1968;45:643–648
  25. Prasanphanich AF, Lane SR, Figueroa SD, Ma L, Rold TL, Sieckman GL, et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based. In vivo. 2007;21:1–16
  26. Rogers BE, Bigott HM, McCarthy DW, Manna DD, Joonyoung K, Sharp TL, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjugate Chem. 2003;14(4):756–763
  27. van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine. 2003;20:307–311
  28. Garcia-Garayoa E, Maes V, Blaeuenstein P, Blanc A, Hohn A, Tourwe D, et al. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl Med Bio. 2006;33:495–503
  29. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004;24:357–397
  30. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Bio. 2005;32:733–740
  31. Bandoli G, Tisato F, Dolmella A, Agostini S. Structural overview of technetium compounds (2000–2004). Coord Chem Rev. 2006;250:561–573
  32. Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev. 1999;99:2205–2218
  33. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, et al. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res. 2003;23:63–70
  34. Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Kannan R, et al. Radiochemical investigations of gastrin-releasing peptide receptor-specific [99mTc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr=2,3-diaminopropionic acid and X=H2O or P(CH2OH)3. Cancer Res. 2003;63:4082–4088
  35. Varga G, Reidelberger RD, Liehr RM, Bussjaeger LJ, Coy DH, Solomon TE. Effects of potent bombesin antagonist on exocrine pancreatic secretion in rats. Peptides. 1991;12:493–497
  36. Fanger BO, Wade AC, Cardin AD. Characterization of the murine pancreatic receptor for gastrin releasing peptide and bombesin. Regul Pept. 1991;32:241–251
  37. Huang SC, Yu DH, Wank SA, Gardner JD, Jensen RT. Characterization of the bombesin receptor on mouse pancreatic acini by chemical cross-linking. Peptides. 1990;11:1143–1150
  38. Kane MA, Kelley K, Ross SE, Portanova LB. Isolation of a gastrin releasing peptide receptor from normal rat pancreas. Peptides. 1991;12:207–213
  39. La Bella R, Garcia-Garayoa E, Baehler M, Blaeuenstein P, Schibli R, Conrath P, et al. A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjugate Chem. 2002;13:599–604
  40. Alves S, Correia JDG, Santos I, Veerendra B, Sieckman GL, Hoffman TJ, et al. Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M(CO)3]+ moiety. Nucl Med Biol. 2006;33:625–634
  41. La Bella R, Garcia-Garayoa E, Langer M, Bläuenstein P, Beck-Sickinger AG, Schubiger PA. In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med and Biol. 2002;29:553–560
  42. Mundwiler S, Candreia L, Häfliger P, Ortner K, Alberto R. Preparation of no-carrier-added technetium-99m complexes via metal-assisted cleavage from a solid phase. Bioconjugate Chem. 2004;15:195–202

PII: S0969-8051(07)00299-5

doi: 10.1016/j.nucmedbio.2007.11.007

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 263-272 , April 2008

Article Tools

* Image Usage & Resolution